When.com Web Search

  1. Ads

    related to: darzalex velcade and dexamethasone gel dosage solution

Search results

  1. Results From The WOW.Com Content Network
  2. Daratumumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Daratumumab/hyaluronidase

    It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]

  3. Daratumumab - Wikipedia

    en.wikipedia.org/wiki/Daratumumab

    Daratumumab was given priority review status by the US Food and Drug Administration (FDA) for multiple myeloma as a combination therapy (second line). [24] Daratumumab phase III trials for multiple myeloma show great promise in combination therapy with lenalidomide and dexamethasone, [32] as well as with bortezomib and dexamethasone. [33 ...

  4. Bortezomib/dexamethasone - Wikipedia

    en.wikipedia.org/wiki/Bortezomib/dexamethasone

    Bortezomib/dexamethasone is a combination drug against multiple myeloma. [1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex ). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid .

  5. J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group

    www.aol.com/news/j-j-files-sbla-darzalex...

    For premium support please call: 800-290-4726 more ways to reach us

  6. GSK's Blood Cancer Drug Shows Improved Survival ... - AOL

    www.aol.com/finance/gsks-blood-cancer-drug-shows...

    The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) in combination with ...

  7. Bortezomib - Wikipedia

    en.wikipedia.org/wiki/Bortezomib

    The phase III demonstrated the superiority of bortezomib over a high-dose dexamethasone regimen (e.g. median TTP 6.2 vs 3.5 months, and 1-year survival 80% vs 66%). [7] New studies show that bortezomib may potentially help recover from vincristine treatment in treating acute lymphoblastic leukemia, when replacing vincristine in the process.

  1. Ads

    related to: darzalex velcade and dexamethasone gel dosage solution